- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
BMPR1A Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP2004a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
BMPR1A Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | P36894 |
| Other Accession | NP_004320 |
| Clone Names | 2072407 |
| Calculated MW | 60198 Da |
BMPR1A Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 657 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP2004a was selected from the N-term region of human BMPR1A . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
BMPR1A Antibody (N-term) Blocking Peptide - Protein Information | |
| Name BMPR1A | |
| Synonyms ACVRLK3, ALK3 | |
| Function On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP-2 and BMP-4 | |
| Cellular Location Membrane; Single-pass type I membrane protein | |
| Tissue Location Highly expressed in skeletal muscle. | |
BMPR1A Antibody (N-term) Blocking Peptide - Related products
AP2004a: BMPR1A Antibody (N-term)
AP2004b: BMPR1A Antibody (C-term)
AP2004c: BMPR1A Antibody (N-term K36)
AP2004d: BMPR1A Antibody (Center C180)
AP2004e: BMPR1A Antibody (N-term)
AP2004f: BMPR1A Antibody (N-term)
RI10618: BMPR1A predesign siRNA
LY11707a: BMPR1A Over-expression Lysate
BP2004a: BMPR1A Antibody (N-term) Blocking Peptide
BP2004b: BMPR1A Antibody (C-term) Blocking Peptide
BP2004c: BMPR1A Antibody (N-term K36) Blocking Peptide
BP2004d: BMPR1A Antibody (Center C180) Blocking Peptide
BP2004e: BMPR1A Antibody (N-term) Blocking Peptide
BMPR1A Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.
REFERENCES
Waite, K.A., et al., Hum. Mol. Genet. 12(6):679-684 (2003).Zhou, X.P., et al., Am. J. Hum. Genet. 69(4):704-711 (2001).Astrom, A.K., et al., Mamm. Genome 10(3):299-302 (1999).ten Dijke, P., et al., Oncogene 8(10):2879-2887 (1993).Ide, H., et al., Cytogenet. Cell Genet. 81 (3-4), 285-286 (1998).
